Booting Earth Optimization System
Thank you for your patience. Your civilization is very important to us.
FOLFIRINOX (Folinic acid, Fluorouracil, Irinotecan, Oxaliplatin)
Treatment for Pancreatic cancer
Typical Dosage: Standard regimen, e.g., Oxaliplatin 85 mg/m2, Irinotecan 180 mg/m2, Leucovorin 400 mg/m2, 5-FU 400 mg/m2 bolus then 2400 mg/m2 infusion, every 2 weeks
Effectiveness
80%
Safety Score
25%
Clinical Trials
100
Participants
3K
Comparative Safety Scale(Higher is safer)
Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
25
DangerousModerateSafe
Treatment Details
Dosage Range
Standard regimen, e.g., Oxaliplatin 85 mg/m2, Irinotecan 180 mg/m2, Leucovorin 400 mg/m2, 5-FU 400 mg/m2 bolus then 2400 mg/m2 infusion, every 2 weeks
Time to Effect
1-2 months
Treatment Duration
6-12 months, until progression or unacceptable toxicity
Evidence Quality
HIGHConfidence Score
90%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$150,000
Monitoring:$15,000
Side Effect Mgmt:$30,000
Total Annual:$195,000
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
POORICER
$182,756/QALY
QALYs Gained
0.26
Outcome-Based Costs
Cost per Responder
$616,962
Comparison vs Gemcitabine
Cost Difference
+$125,000/year
More expensive
QALY Difference
+0.26 QALYs
Better outcomes
Dominance
No dominance
FOLFIRINOX (Folinic acid, Fluorouracil, Irinotecan, Oxaliplatin) Outcomes
for Pancreatic cancer
Efficacy Outcomes
Overall Effectiveness
+80%
Response Rate
+32%
Common Side Effects
Neutropenia (Grade 3/4)
+46%
Diarrhea (Grade 3/4)
+13%
Peripheral neuropathy (Grade 3/4)
+9%
Fatigue (Grade 3/4)
+24%
Vomiting (Grade 3/4)
+15%
Sources:
WARNING: LIMITED TRIALS AVAILABLE
You can search for trials, but you probably can't join any because the 1% Treaty hasn't passed yet. Most trials are severely limited by lack of funding and bureaucratic barriers. Help change this!
Active Clinical Trials
3 active trials recruiting for FOLFIRINOX (Folinic acid, Fluorouracil, Irinotecan, Oxaliplatin) in Pancreatic cancer
FOLFIRINOX Versus OncoSil™ in Addition to FOLFIRINOX in Patients With Locally Advanced Pancreatic Adenocarcinoma
NCT05466799ACTIVE NOT RECRUITINGPHASE2
88 participants
INTERVENTIONAL
Adelaide, Australia +13 more
Started: Apr 26, 2023
Tumor Subtypes in Subjects on FOLFIRINOX With Non-Metastatic Pancreatic Cancer
NCT03977233RECRUITINGPHASE2
45 participants
INTERVENTIONAL
Chapel Hill, United States
Started: Jun 12, 2019
Efficacy of Gembrax Followed by Folfirinox Versus Folfirinox Alone in First Metastatic Line Pancreatic Cancer Patients
NCT05065801RECRUITINGPHASE2
162 participants
INTERVENTIONAL
Grenoble, France +7 more
Started: Jan 11, 2022
Completed Clinical Trials
9 completed trials for FOLFIRINOX (Folinic acid, Fluorouracil, Irinotecan, Oxaliplatin) in Pancreatic cancer
Efficacy and Tolerance Evaluation in FOLFIRINOX Dose Adjusted in Elderly Patients With a Metastatic Pancreatic Cancer
NCT02143219COMPLETEDPHASE2
72 participants
INTERVENTIONAL
Angers, France +5 more
Started: Jul 31, 2014
Observational Retrospective Study of Evaluation of Prognostic Factors in Advanced Pancreatic Cancer Patients Treated With FOLFIRINOX
NCT03590275COMPLETED
343 participants
OBSERVATIONAL
Ponderano, Italy +6 more
Started: Oct 2, 2017
Phase 3 Study of FOLFIRINOX (mFFX) +/- SBRT in Locally Advanced Pancreatic Cancer
NCT01926197COMPLETEDPHASE3
27 participants
INTERVENTIONAL
Los Angeles, United States +8 more
Started: Aug 14, 2013
Modified FOLFIRINOX for Gemcitabine Refractory Pancreatic Cancer: A Phase II Multicenter Trial
NCT02440958COMPLETEDPHASE2
50 participants
INTERVENTIONAL
Started: Aug 28, 2015
Study of Modified FOLFIRINOX in Advanced Pancreatic Cancer
NCT01523457COMPLETEDPHASE2
75 participants
INTERVENTIONAL
New Haven, United States
Started: Oct 1, 2011
First-line Metastatic Pancreatic Cancer : FOLFIRINOX +/- LV5FU2 in Maintenance Versus Firgem
NCT02352337COMPLETEDPHASE2
276 participants
INTERVENTIONAL
Angers, France +53 more
Started: Jan 12, 2015
CPI-613 in Combination With Modified FOLFIRINOX in Locally Advanced Pancreatic Cancer
NCT03699319COMPLETEDPHASE1, PHASE2
49 participants
INTERVENTIONAL
Cleveland, United States
Started: Dec 7, 2018
Evaluation of Efficacy and Safety of Neoadjuvant Treatment With Pamrevlumab in Combination With Chemotherapy (Either Gemcitabine Plus Nab-paclitaxel or FOLFIRINOX) in Participants With Locally Advanced, Unresectable Pancreatic Cancer
NCT03941093COMPLETEDPHASE3
284 participants
INTERVENTIONAL
Phoenix, United States +89 more
Started: May 10, 2019
A Phase II Study of Neoadjuvant FOLFIRINOX
NCT02178709COMPLETEDPHASE2
48 participants
INTERVENTIONAL
Indianapolis, United States
Started: Jun 3, 2014
Showing 20 of 101 total trials